Nasdaq · CIK 0001211583
FENC FENNEC PHARMACEUTICALS INC.
Insider trading from SEC Form 4. Last filing 12 d ago. Close $10.71 on Oct 9, 2026, +86% from the 52-week low and -16% from the high.
FENNEC PHARMACEUTICALS INC. (FENC) has 117 SEC Form 4 filings on file from 11 insiders, the latest filed on Oct 1, 2026. In the last 90 days insiders made 0 open-market buys worth $0 and 2 open-market sells worth $281k, net -$281k.
35 open-market trades have been scored at FENC. The newest: Marco Maria Brughera (director) sold $160k of stock on Sep 15, 2026, filed Sep 16, 2026, scored 19 (weak), under a 10b5-1 plan. The largest of the 35 shown: Southpoint Capital Advisors LP (10% owner) sold $7.5M on Dec 24, 2025, scored 55 (moderate). 2 insiders sold within 14 days of each other around Sep 15, 2026.
FENC closed at $10.71 on Oct 9, 2026, 86% above its 52-week low and 16% below its 52-week high.
19 Form 144 notices of planned sales are on file, the latest filed Dec 5, 2025.
Last 90 days
Net insider value
-$281k
more sold than bought
Buys
0
$0 by 0 insiders
Sells
2
$281k by 2 insiders
Insiders on file
11
with a Form 4 at this company
Price and insider trades, last year
FENCOct 9, 2026 · close 10.71
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at FENNEC PHARMACEUTICALS INC., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 19Weak | Marco Maria Brughera director sell | $160k 15,545 shares | -100% | - | |
| 6Weak | Rosty Raykov other sell | $121k 10,000 shares | -7% | - | |
| 0Weak | Rosty Raykov director sell | $94k 9,747 shares | -7% | +71% from low-1% from high | |
| 0Weak | Chris A Rallis director sell | $59k 8,346 shares | -12% | +23% from low-28% from high | |
| 0Weak | Rosty Raykov director sell | $70k 10,781 shares | -8% | +13% from low-34% from high | |
| 0Weak | Rosty Raykov director sell | $69k 10,946 shares | -9% | +28% from low-35% from high | |
| 0Weak | Rosty Raykov director sell | $84k 10,079 shares | -9% | +64% from low-17% from high | |
| 0Weak | Rosty Raykov director sell | $80k 10,349 shares | -10% | +56% from low-21% from high | |
| 2Weak | Rosty Raykov director sell | $78k 10,312 shares | -10% | +53% from low-22% from high | |
| 55Moderate | Southpoint Capital Advisors LP owner sell | $7.5M 1,000,000 shares | -27% | +53% from low-22% from high | |
| 8Weak | Rosty Raykov director sell | $75k 10,000 shares | -11% | +51% from low-24% from high | |
| 31Weak | Southpoint Capital Advisors LP owner sell | $170k 19,341 shares | -1% | +117% from low-11% from high | |
| 45Moderate | Southpoint Capital Advisors LP owner sell | $2.0M 246,018 shares | -6% | +97% from low-20% from high | |
| 17Weak | Rosty Raykov director sell | $81k 10,000 shares | -11% | +107% from low-17% from high | |
| 0Weak | Chris A Rallis director sell | $16k 1,775 shares | -3% | +115% from low-13% from high | |
| 47Moderate | Southpoint Capital Advisors LP owner sell | $636k 67,114 shares | -2% | +138% from low-4% from high | |
| 25Weak | Rosty Raykov director sell | $98k 10,000 shares | -11% | +144% from low-1% from high | |
| 9Weak | Rosty Raykov director sell | $89k 10,000 shares | -16% | +130% from low-1% from high | |
| 9Weak | Rosty Raykov director sell | $81k 10,000 shares | -15% | +105% from low-10% from high | |
| 17Weak | Rosty Raykov director sell | $86k 10,000 shares | -14% | +121% from low0% from high | |
| 0Weak | Chris A Rallis director sell | $9,746 1,119 shares | -2% | +112% from low-4% from high | |
| 9Weak | Rosty Raykov director sell | $78k 10,000 shares | -13% | +98% from low-5% from high | |
| 30Weak | Rosty Raykov director sell | $113k 16,667 shares | -19% | +71% from low-3% from high | |
| 43Moderate | Jeffrey S. Hackman Chief Executive Officer buy | $105k 15,000 shares | - | +71% from low-3% from high | |
| 8Weak | Rosty Raykov director sell | $63k 10,000 shares | -16% | +57% from low-11% from high | |
| 0Weak | Chris A Rallis director sell | $6,975 1,409 shares | -3% | +26% from low-29% from high | |
| 15Weak | Rosty Raykov director sell | $53k 10,000 shares | -14% | +32% from low-25% from high | |
| 8Weak | Rosty Raykov director sell | $68k 10,000 shares | -13% | - | |
| 0Weak | Chris A Rallis director sell | $8,089 1,186 shares | -2% | - | |
| 16Weak | Rosty Raykov director sell | $67k 10,000 shares | -12% | - | |
| 7Weak | Rosty Raykov director sell | $61k 10,000 shares | -11% | - | |
| 3Weak | Rosty Raykov director sell | $4,808 796 shares | -1% | - | |
| 3Weak | Rosty Raykov director sell | $10k 1,635 shares | -2% | - | |
| 0Weak | Chris A Rallis director sell | $39k 6,409 shares | -11% | - | |
| 0Weak | Rosty Raykov director sell | $10k 2,431 shares | -4% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Dec 5, 2025 | ROSTISLAV RAYKOV Director | 10,000 0.04% of outstanding | $75k | Dec 5, 2025 | $179k |
| Nov 5, 2025 | ROSTISLAV RAYKOV Director | 10,000 0.04% of outstanding | $81k | Nov 5, 2025 | $268k |
| Oct 10, 2025 | CHRIS A RALLIS Director | 1,775 0.01% of outstanding | $16k | Oct 10, 2025 | none |
| Oct 6, 2025 | ROSTISLAV RAYKOV Director | 10,000 0.04% of outstanding | $98k | Oct 6, 2025 | $170k |
| Sep 4, 2025 | ROSTISLAV RAYKOV Director | 10,000 0.04% of outstanding | $89k | Sep 4, 2025 | $245k |
| Aug 5, 2025 | ROSTISLAV RAYKOV Director | 10,000 0.04% of outstanding | $81k | Aug 5, 2025 | $277k |
| Jul 3, 2025 | ROSTISLAV RAYKOV Director | 10,000 0.04% of outstanding | $86k | Jul 3, 2025 | $306k |
| Jun 5, 2025 | ROSTISLAV RAYKOV Director | 10,000 0.04% of outstanding | $78k | Jun 5, 2025 | $229k |
| May 16, 2025 | Raykov Rosty Director | 16,667 0.06% of outstanding | $100k | May 16, 2025 | $184k |
| May 5, 2025 | ROSTISLAV RAYKOV Director | 10,000 0.04% of outstanding | $63k | May 5, 2025 | $120k |
| Apr 4, 2025 | ROSTISLAV RAYKOV Director | 10,000 0.04% of outstanding | $53k | Apr 4, 2025 | $195k |
| Mar 5, 2025 | ROSTISLAV RAYKOV Director | 10,000 0.04% of outstanding | $68k | Mar 5, 2025 | $127k |
| Feb 14, 2025 | CHRIS A RALLIS Director | 1,186 0.00% of outstanding | $8,089 | Feb 14, 2025 | $39k |
| Feb 5, 2025 | ROSTISLAV RAYKOV Director | 10,000 0.04% of outstanding | $67k | Feb 5, 2025 | $76k |
| Jan 6, 2025 | ROSTISLAV RAYKOV Director | 10,000 0.04% of outstanding | $61k | Jan 6, 2025 | $25k |
| Dec 5, 2024 | ROSTISLAV RAYKOV Director | 796 0.00% of outstanding | $4,808 | Dec 5, 2024 | $33k |
| Dec 3, 2024 | ROSTISLAV RAYKOV Director | 1,635 0.01% of outstanding | $10k | Dec 3, 2024 | $36k |
| Dec 2, 2024 | CHRIS A RALLIS Director | 6,409 0.02% of outstanding | $39k | Dec 2, 2024 | $6,369 |
| Nov 4, 2024 | ROSTISLAV RAYKOV Director | 2,431 0.01% of outstanding | $10k | Nov 4, 2024 | $25k |
Transactions
The newest 50 of 187 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | Jeffrey S. Hackman Chief Executive Officer | AGrant or award Common Shares | +1,159 | $0.00 | $0 | 67,461 | 12 d ago |
| Sep 30, 2026 | Terry L Evans Chief Commercial Officer | AGrant or award Common Shares | +168 | $0.00 | $0 | 21,687 | 12 d ago |
| Sep 30, 2026 | Christiana Marie Cioffi Chief Strategy Officer | AGrant or award Common shares | +156 | $0.00 | $0 | 24,800 | 12 d ago |
| Sep 30, 2026 | Pierre Sargis Sayad Chief Medical Officer | AGrant or award Common Shares | +168 | $0.00 | $0 | 9,687 | 12 d ago |
| Sep 30, 2026 | Robert Andrade CHIEF FINANCIAL OFFICER | AGrant or award Common shares | +1,703 | $0.00 | $0 | 243,009 | 12 d ago |
| Sep 15, 2026 | Marco Maria Brughera director | MOption exercise Common Shares10b5-1 | +15,545 | $2.11 | $33k | 15,545 | 27 d ago |
| Sep 15, 2026 | Marco Maria Brughera director | SOpen-market sale Common Shares10b5-1 | -15,545 | $10.29 | $160k | 0 | 27 d ago |
| Sep 15, 2026 | Marco Maria Brughera director | MOption exercise Stock Optionderivative10b5-1 | -15,545 | $0.00 | $0 | 220,000 | 27 d ago |
| Aug 31, 2026 | Rosty Raykov other | AGrant or award Common shares10b5-1 | +2,778 | $0.00 | $0 | 134,411 | 42 d ago |
| Sep 1, 2026 | Rosty Raykov other | SOpen-market sale Common shares10b5-1 | -10,000 | $12.11 | $121k | 124,411 | 42 d ago |
| Jun 10, 2026 | Marco Maria Brughera director | AGrant or award Stock Optionderivative | +20,000 | $8.70 | $174k | 235,545 | Jun 10, 2026 |
| Jun 10, 2026 | Jodi A Cook director | AGrant or award Stock Optionsderivative | +20,000 | $8.70 | $174k | 160,000 | Jun 10, 2026 |
| Jun 10, 2026 | Chris A Rallis director | AGrant or award Stock Optionderivative | +20,000 | $8.70 | $174k | 200,000 | Jun 10, 2026 |
| Jun 10, 2026 | Khalid Islam director | AGrant or award Stock Optionderivative | +25,000 | $8.70 | $218k | 250,000 | Jun 10, 2026 |
| May 31, 2026 | Rosty Raykov director | AGrant or award Common shares10b5-1 | +2,778 | $0.00 | $0 | 124,229 | Jun 2, 2026 |
| Jun 1, 2026 | Rosty Raykov director | MOption exercise Common shares10b5-1 | +15,597 | $2.45 | $38k | 139,826 | Jun 2, 2026 |
| Jun 1, 2026 | Rosty Raykov director | SOpen-market sale Common shares10b5-1 | -9,747 | $9.62 | $94k | 130,079 | Jun 2, 2026 |
| Jun 1, 2026 | Rosty Raykov director | MOption exercise Stock Optionsderivative10b5-1 | -15,597 | $2.45 | $38k | 1,556,195 | Jun 2, 2026 |
| May 31, 2026 | Robert Andrade CHIEF FINANCIAL OFFICER | AGrant or award Common shares | +1,703 | $0.00 | $0 | 289,269 | Jun 1, 2026 |
| May 31, 2026 | Christiana Marie Cioffi Chief Strategy Officer | AGrant or award Common shares | +156 | $0.00 | $0 | 24,176 | Jun 1, 2026 |
| May 31, 2026 | Terry L Evans Chief Commercial Officer | AGrant or award Common Shares | +168 | $0.00 | $0 | 21,015 | Jun 1, 2026 |
| May 31, 2026 | Jeffrey S. Hackman Chief Executive Officer | AGrant or award Common Shares | +1,159 | $0.00 | $0 | 62,825 | Jun 1, 2026 |
| May 31, 2026 | Pierre Sargis Sayad Chief Medical Officer | AGrant or award Common Shares | +168 | $0.00 | $0 | 21,015 | Jun 1, 2026 |
| May 11, 2026 | Chris A Rallis director | MOption exercise Common Shares10b5-1 | +14,344 | $2.44 | $35k | 71,423 | May 12, 2026 |
| May 11, 2026 | Chris A Rallis director | SOpen-market sale Common Shares10b5-1 | -8,346 | $7.04 | $59k | 63,077 | May 12, 2026 |
| May 11, 2026 | Chris A Rallis director | MOption exercise Stock Optionderivative10b5-1 | -14,344 | $2.44 | $35k | 186,189 | May 12, 2026 |
| Apr 30, 2026 | Terry L Evans Chief Commercial Officer | MOption exercise Common Shares | +168 | $0.00 | $0 | 20,847 | May 1, 2026 |
| Apr 30, 2026 | Rosty Raykov director | MOption exercise Common shares10b5-1 | +2,778 | $0.00 | $0 | 116,634 | May 1, 2026 |
| Apr 30, 2026 | Jeffrey S. Hackman Chief Executive Officer | MOption exercise Common Shares | +1,159 | $0.00 | $0 | 61,666 | May 1, 2026 |
| Apr 30, 2026 | Pierre Sargis Sayad Chief Medical Officer | MOption exercise Common Shares | +168 | $0.00 | $0 | 20,847 | May 1, 2026 |
| Apr 30, 2026 | Robert Andrade CHIEF FINANCIAL OFFICER | MOption exercise Common shares | +1,703 | $0.00 | $0 | 287,566 | May 1, 2026 |
| Apr 30, 2026 | Christiana Marie Cioffi Chief Strategy Officer | MOption exercise Common shares | +155 | $0.00 | $0 | 24,020 | May 1, 2026 |
| May 1, 2026 | Rosty Raykov director | MOption exercise Common shares10b5-1 | +15,598 | $2.45 | $38k | 132,232 | May 1, 2026 |
| May 1, 2026 | Rosty Raykov director | SOpen-market sale Common shares10b5-1 | -10,781 | $6.47 | $70k | 121,451 | May 1, 2026 |
| May 1, 2026 | Rosty Raykov director | MOption exercise Stock Optionsderivative10b5-1 | -15,598 | $2.45 | $38k | 1,571,792 | May 1, 2026 |
| Mar 31, 2026 | Pierre Sargis Sayad Chief Medical Officer | MOption exercise Common Shares | +18,456 | $0.00 | $0 | 18,456 | Apr 2, 2026 |
| Mar 31, 2026 | Robert Andrade CHIEF FINANCIAL OFFICER | MOption exercise Common shares | +14,724 | $0.00 | $0 | 271,380 | Apr 2, 2026 |
| Mar 31, 2026 | Christiana Marie Cioffi Chief Strategy Officer | MOption exercise Common shares | +17,106 | $0.00 | $0 | 21,806 | Apr 2, 2026 |
| Mar 31, 2026 | Terry L Evans Chief Commercial Officer | MOption exercise Common Shares | +18,456 | $0.00 | $0 | 18,456 | Apr 2, 2026 |
| Mar 31, 2026 | Rosty Raykov director | AGrant or award Common shares10b5-1 | +5,208 | $0.00 | $0 | 109,204 | Apr 2, 2026 |
| Mar 31, 2026 | Jeffrey S. Hackman Chief Executive Officer | MOption exercise Common Shares | +16,695 | $0.00 | $0 | 45,405 | Apr 2, 2026 |
| Apr 1, 2026 | Rosty Raykov director | MOption exercise Common shares10b5-1 | +15,598 | $2.45 | $38k | 124,802 | Apr 2, 2026 |
| Mar 31, 2026 | Robert Andrade CHIEF FINANCIAL OFFICER | MOption exercise Common shares | +2,213 | $0.00 | $0 | 273,593 | Apr 2, 2026 |
| Mar 31, 2026 | Christiana Marie Cioffi Chief Strategy Officer | MOption exercise Common shares | +158 | $0.00 | $0 | 21,964 | Apr 2, 2026 |
| Mar 31, 2026 | Terry L Evans Chief Commercial Officer | MOption exercise Common shares | +171 | $0.00 | $0 | 18,627 | Apr 2, 2026 |
| Mar 31, 2026 | Pierre Sargis Sayad Chief Medical Officer | MOption exercise Common shares | +171 | $0.00 | $0 | 18,627 | Apr 2, 2026 |
| Mar 31, 2026 | Jeffrey S. Hackman Chief Executive Officer | MOption exercise Common Shares | +1,159 | $0.00 | $0 | 46,564 | Apr 2, 2026 |
| Apr 1, 2026 | Rosty Raykov director | SOpen-market sale Common shares10b5-1 | -10,946 | $6.31 | $69k | 113,856 | Apr 2, 2026 |
| Mar 28, 2026 | Christiana Marie Cioffi Chief Strategy Officer | MOption exercise Common shares | +1,901 | $0.00 | $0 | 23,865 | Apr 2, 2026 |
| Mar 28, 2026 | Robert Andrade CHIEF FINANCIAL OFFICER | MOption exercise Common shares | +12,270 | $0.00 | $0 | 285,863 | Apr 2, 2026 |
50 of 187 rows shown.
Insiders
Everyone who has filed a Form 4 here.
- Robert AndradeCHIEF FINANCIAL OFFICER
- Marco Maria Brugheradirector
- Christiana Marie CioffiChief Strategy Officer
- Jodi A Cookdirector
- Terry L EvansChief Commercial Officer
- Jeffrey S. HackmanChief Executive Officer
- Khalid Islamdirector
- Chris A Rallisdirector
- Rosty Raykovdirector, other
- Pierre Sargis SayadChief Medical Officer
- Southpoint Capital Advisors LPowner
Questions about FENC
Answered from the filings on this page, as of the latest one.
Are insiders buying FENC?
As of Oct 1, 2026, SEC Form 4 filings show 0 open-market buys worth $0 by 0 insiders and 2 open-market sells worth $281k by 2 insiders at FENNEC PHARMACEUTICALS INC. in the last 90 days, net -$281k. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade FENC on the open market?
Marco Maria Brughera (director) sold $160k of FENC on Sep 15, 2026 and filed the Form 4 on Sep 16, 2026. InsiderTell scored 19 (weak), under a 10b5-1 plan, with 2 insiders on the same side within 14 days.
How many insiders file Form 4 at FENNEC PHARMACEUTICALS INC.?
11 people have filed a Form 4 at FENNEC PHARMACEUTICALS INC., among them Robert Andrade (CHIEF FINANCIAL OFFICER), Marco Maria Brughera (director), Christiana Marie Cioffi (Chief Strategy Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.